# 2026-05913: FDA Fixes Blunder: One Generic Drug Stays on Shelves

2026-05913, Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-26, effective 2025-10-23; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-05913
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05913
- Title: Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications; Correction
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 14703
- Published: 2026-03-26
- Effective: 2025-10-23
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Fixes Blunder: One Generic Drug Stays on Shelves

## Summary

The FDA fixed a mistake about pulling approvals for 72 generic drug applications. One drug, a valproic acid capsule from Upsher-Smith Laboratories, won’t lose its approval because the company asked to keep it. This means the drug stays available, and the change took effect before October 23, 2025.

## Abstract

The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on September 24, 2025 (90 FR 183), appearing on page 45942 in FR Doc. 2025-18453. The document announced the withdrawal of approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants, withdrawn as of October 23, 2025. The document indicated that FDA was withdrawing approval of the ANDA 070631 for valproic acid, capsule, 250 milligrams, held by Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369. Before FDA withdrew the approval of this ANDA, Upsher-Smith Laboratories, LLC, 6701 Evenstad Dr., Maple Grove, MN 55369, informed FDA that they did not want the approval of the ANDA withdrawn. Because Upsher-Smith Laboratories, LLC, timely requested that approval of the ANDA not be withdrawn, the approval is still in effect. This notice corrects this error.

## Effects PRIA read

- Valproic Acid ANDA Approval Retained: benefit, low. The FDA corrected a prior notice to say that ANDA 070631 (valproic acid capsule, 250 milligrams) held by Upsher-Smith Laboratories, LLC remains approved because the company timely asked that the approval not be withdrawn. The earlier document had listed this ANDA among 72 approvals withdrawn as of…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05913 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/26/2026-05913/elite-laboratories-inc-et-al-withdrawal-of-approval-of-72-abbreviated-new-drug-applications)
- [2026-05913 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-26/pdf/2026-05913.pdf)

## Related
- [Previous: 2026-05912, Bulk Manufacturer of Controlled Substances Application: SpecGx LLC](https://policyrisk.com/federal-register/2026-05912)
- [Next: 2026-05914, Notice Pursuant to the National Cooperative Research and Production Act of 1993…](https://policyrisk.com/federal-register/2026-05914)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05913 (as of 2026-06-08).
